Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease.

Trial Profile

Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Sodium oligomannurarate (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Shanghai Green Valley Pharmaceutical
  • Most Recent Events

    • 26 Jan 2015 Duration of assessment of primary end point changed from 4 weeks, 12 weeks, 24 weeks to 12 weeks only as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top